Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral topotecan plus whole-brain radiation therapy versus whole-brain radiation therapy alone in brain metastases from non-small cell lung cancer
2006-002074-22Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of topotecan in brain metastases and non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: overall survival. Started Aug 2006; status: completed.
02
Drugs
topotecan
03
Conditions
brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-002074-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002074-22.